TABLE 1.
No. of expt and condition | Immunogen | No. of spleen cells | Spleen cell stimulant | No. of schizonts/well (mean ± SD) | % Inhibition |
---|---|---|---|---|---|
Expt 1 | |||||
BALB/c hepatocytes with BALB/c effector cells | Lipofectin | 1 × 106 | MAP4(PyCSP57–70) | 96, 108, 90 (98 ± 9) | |
Lipofectin | 1 × 106 | PfSSP2-15 | 113, 117, 91 (107 ± 14) | ||
MAP4(PyCSP57–70) | 1 × 106 | MAP4(PyCSP57–70) | 24, 21, 17 (21 ± 4) | 79 | |
MAP4(PyCSP57–70) | 1 × 106 | PfSSP2-15 | 87, 99, 88 (91 ± 7) | 15 | |
Expt 2 | |||||
BALB/c hepatocytes with BALB/c effector cells | Lipofectin | 1 × 106 | MAP4(PyCSP57–70) | 66, 71, 76 (71 ± 4) | |
Lipofectin | 5 × 105 | MAP4(PyCSP57–70) | 59, 57, 73 (63 ± 7) | ||
MAP4(PyCSP57–70) | 1 × 106 | MAP4(PyCSP57–70) | 29, 21, 36 (28 ± 6) | 60 | |
MAP4(PyCSP57–70) | 5 × 105 | MAP4(PyCSP57–70) | 42, 29, 27 (32 ± 6) | 49 | |
MAP4(PyCSP57–70) | 2.5 × 105 | MAP4(PyCSP57–70) | 61, 62, 60 (61 ± 0.8) | 3 | |
MAP4(PyCSP57–70) | 1 × 105 | MAP4(PyCSP57–70) | 74, 70, 73 (72 ± 1.6) | ||
CD8+ depletion | MAP4(PyCSP57–70) | 1 × 106 | MAP4(PyCSP57–70) | 60, 59, 70 (63 ± 5) | 11 |
MAP4(PyCSP57–70) | 5 × 105 | MAP4(PyCSP57–70) | 63, 56, 66 (61 ± 4) | 3 | |
5 μM 1400W (iNOS inhibitor) | MAP4(PyCSP57–70) | 1 × 106 | MAP4(PyCSP57–70) | 63, 83, 66 (70 ± 9) | 1 |
C57BL/6 hepatocytes with BALB/c effector cells | Lipofectin | 1 × 106 | MAP4(PyCSP57–70) | 156, 152, 137 (148 ± 8) | |
Lipofectin | 5 × 105 | MAP4(PyCSP57–70) | 200, 170, 183 (177 ± 6) | ||
MAP4(PyCSP57–70) | 1 × 106 | MAP4(PyCSP57–70) | 120, 176, 145 (147 ± 23) | 1 | |
MAP4(PyCSP57–70) | 5 × 105 | MAP4(PyCSP57–70) | 147, 169, 198 (171 ± 20) | 3 | |
MAP4(PyCSP57–70) | 2.5 × 105 | MAP4(PyCSP57–70) | 135, 154, 159 (150 ± 3) | 15 | |
MAP4(PyCSP57–70) | 1 × 105 | MAP4(PyCSP57–70) | 160, 159, 142 (156 ± 4) | 11 | |
CD8+ depletion | MAP4(PyCSP57–70) | 1 × 106 | MAP4(PyCSP57–70) | 165, 149, 161 (158 ± 7) | 0 |
MAP4(PyCSP57–70) | 5 × 105 | MAP4(PyCSP57–70) | 174, 148, 156 × (161 ± 13) | 12 |